

Company Overview

Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

Abeona Therapeutics Announces Strategic Review

Sep 3 2019, 9:00 AM EDT

Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates

Aug 9 2019, 4:15 PM EDT

Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA

Jul 25 2019, 9:15 AM EDT

Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	160.77m
Last Price	\$3.26
52-Week	\$1.46 - \$14.10

09/20/2019 04:00 PM EDT

Investor Relations

Sofia Warner
Senior Director, Investor Relations
T: +1 (646) 813-4710
swarner@abeonatherapeutics.com

Management Team

João Siffert, MD

Chief Executive Officer, Head of Research & Development and Chief Medical Officer

Timothy J. Miller, PhD

President & Chief Scientific Officer

Christine Silverstein

Chief Financial Officer

Max Colao

Chief Business Officer

Edward Carr

Chief Accounting Officer

Edward Sturchio

Senior Vice President, General Counsel & Corporate Secretary

Juan Ruiz, MD, PhD

Head of European Medical Affairs

Jay Bircher

Senior Vice President, Quality & Technical Operations

Victor Paulus, Ph.D

Senior Vice President, Head of Regulatory Affairs

Jodie Gillon, M.P.H.

Vice President, Patient Advocacy & Community Engagement

Kristina Maximenko

Vice President, Human Resources

Scott Nogi

Vice President, Business Operations

Abeona Therapeutics Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.